Literature DB >> 23040074

Aldosterone and cardiovascular disease: the heart of the matter.

B Julie He1, Mark E Anderson.   

Abstract

Aldosterone contributes to the endocrine basis of heart failure, and studies on cardiac aldosterone signaling have reinforced its value as a therapeutic target. Recent focus has shifted to new roles of aldosterone that appear to depend on coexisting pathologic stimuli, cell type, and disease etiology. This review evaluates recent advances in mechanisms underlying aldosterone-induced cardiac disease and highlights the interplay between aldosterone and Ca(2+)/calmodulin dependent protein kinase II, whose hyperactivity during heart failure contributes to disease progression. Increasing evidence implicates aldosterone in diastolic dysfunction, and there is a need to develop more targeted therapeutics such as aldosterone synthase inhibitors and molecularly specific antioxidants. Despite accumulating knowledge, many questions still persist and will likely dictate areas of future research.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040074      PMCID: PMC3532553          DOI: 10.1016/j.tem.2012.09.004

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  100 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression.

Authors:  Julie Favre; Ji Gao; An Di Zhang; Isabelle Remy-Jouet; Antoine Ouvrard-Pascaud; Brigitte Dautreaux; Brigitte Escoubet; Christian Thuillez; Frédéric Jaisser; Vincent Richard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-25       Impact factor: 4.733

Review 3.  CaMKII in the cardiovascular system: sensing redox states.

Authors:  Jeffrey R Erickson; B Julie He; Isabella M Grumbach; Mark E Anderson
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

4.  Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).

Authors:  Anita Deswal; Peter Richardson; Biykem Bozkurt; Douglas L Mann
Journal:  J Card Fail       Date:  2011-05-31       Impact factor: 5.712

5.  Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.

Authors:  Laurence Amar; Michel Azizi; Joël Menard; Séverine Peyrard; Catherine Watson; Pierre-François Plouin
Journal:  Hypertension       Date:  2010-09-13       Impact factor: 10.190

6.  Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial.

Authors:  Farzin Beygui; Eric Vicaut; Patrick Ecollan; Jacques Machecourt; Eric Van Belle; Faiez Zannad; Gilles Montalescot
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

7.  Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.

Authors:  Akira Uruno; Ken Matsuda; Naoya Noguchi; Takeo Yoshikawa; Masataka Kudo; Fumitoshi Satoh; William E Rainey; Xiao-Gang Hui; Jun-ichi Akahira; Yasuhiro Nakamura; Hironobu Sasano; Hiroshi Okamoto; Sadayoshi Ito; Akira Sugawara
Journal:  J Mol Endocrinol       Date:  2011-01-19       Impact factor: 5.098

8.  β-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes.

Authors:  Javier E López; Bat-Erdene Myagmar; Philip M Swigart; Megan D Montgomery; Stephen Haynam; Marty Bigos; Manoj C Rodrigo; Paul C Simpson
Journal:  Circ Res       Date:  2011-07-21       Impact factor: 17.367

9.  Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.

Authors:  Paul Mulder; Virginie Mellin; Julie Favre; Magali Vercauteren; Isabelle Remy-Jouet; Christelle Monteil; Vincent Richard; Sylvanie Renet; Jean Paul Henry; Arco Y Jeng; Randy L Webb; Christian Thuillez
Journal:  Eur Heart J       Date:  2008-06-27       Impact factor: 29.983

10.  Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans.

Authors:  Thomas Thum; Kerstin Schmitter; Felix Fleissner; Volker Wiebking; Bernd Dietrich; Julian D Widder; Virginija Jazbutyte; Stefanie Hahner; Georg Ertl; Johann Bauersachs
Journal:  Eur Heart J       Date:  2010-10-05       Impact factor: 29.983

View more
  17 in total

Review 1.  A reappraisal of loop diuretic choice in heart failure patients.

Authors:  Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

2.  Chronic atrial ionic remodeling by aldosterone: potentiation of L-type Ca2+ channels and its arrhythmogenic significance.

Authors:  Erick B Ríos-Pérez; Maricela García-Castañeda; Adrián Monsalvo-Villegas; Guillermo Avila
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

3.  Aldosterone downregulates delayed rectifier potassium currents through an angiotensin type 1 receptor-dependent mechanism.

Authors:  Yankun Lv; Yanjun Wang; Xiaoran Zhu; Hua Zhang
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 4.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

5.  Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction.

Authors:  Komei Tanaka; Richard M Wilson; Eric E Essick; Jennifer L Duffen; Philipp E Scherer; Noriyuki Ouchi; Flora Sam
Journal:  Circ Heart Fail       Date:  2014-08-22       Impact factor: 8.790

6.  Aldosterone down-regulates the slowly activated delayed rectifier potassium current in adult guinea pig cardiomyocytes.

Authors:  Yankun Lv; Song Bai; Hua Zhang; Hongxue Zhang; Jing Meng; Li Li; Yanfang Xu
Journal:  Br J Pharmacol       Date:  2015-05-15       Impact factor: 8.739

Review 7.  New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.

Authors:  Irene Capelli; Lorenzo Gasperoni; Marco Ruggeri; Gabriele Donati; Olga Baraldi; Giovanni Sorrenti; Maria Turchese Caletti; Valeria Aiello; Giuseppe Cianciolo; Gaetano La Manna
Journal:  J Nephrol       Date:  2019-04-15       Impact factor: 3.902

8.  Endocrine hypertension secondary to adrenal tumors: clinical course and predictive factors of clinical remission.

Authors:  Uriel Clemente-Gutiérrez; Rafael H Pérez-Soto; Juan D Hernández-Acevedo; Nicole M Iñiguez-Ariza; Enrique Casanueva-Pérez; Juan Pablo Pantoja-Millán; Mauricio Sierra-Salazar; Miguel F Herrera; David Velázquez-Fernández
Journal:  Langenbecks Arch Surg       Date:  2021-06-23       Impact factor: 3.445

9.  The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.

Authors:  Shin-Ichiro Miura; Yasunori Suematsu; Yoshino Matsuo; Sayo Tomita; Asuka Nakayama; Masaki Goto; Tadaaki Arimura; Takashi Kuwano; Eiji Yahiro; Keijiro Saku
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

10.  Exome-Wide Rare Variant Analyses in Sudden Infant Death Syndrome.

Authors:  David J Tester; Leonie C H Wong; Pritha Chanana; Belinda Gray; Amie Jaye; Jared M Evans; Margaret Evans; Peter Fleming; Iona Jeffrey; Marta Cohen; Jacob Tfelt-Hansen; Michael A Simpson; Elijah R Behr; Michael J Ackerman
Journal:  J Pediatr       Date:  2018-09-26       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.